Works matching DE "RALTEGRAVIR"

Results: 569
    1
    2
    3
    4

    Clinical trial of raltegravir, an integrase inhibitor, in HAM/TSP.

    Published in:
    Annals of Clinical & Translational Neurology, 2021, v. 8, n. 10, p. 1970, doi. 10.1002/acn3.51437
    By:
    • Enose‐Akahata, Yoshimi;
    • Billioux, Bridgette Jeanne;
    • Azodi, Shila;
    • Dwyer, Jennifer;
    • Vellucci, Ashley;
    • Ngouth, Nyater;
    • Nozuma, Satoshi;
    • Massoud, Raya;
    • Cortese, Irene;
    • Ohayon, Joan;
    • Jacobson, Steven
    Publication type:
    Article
    5
    6

    Six-Year Immunologic Recovery and Virological Suppression of HIV Patients on LPV/r-Based Second-Line Antiretroviral Treatment: A Multi-Center Real-World Cohort Study in China.

    Published in:
    Frontiers in Pharmacology, 2019, v. 10, p. 1, doi. 10.3389/fphar.2019.01455
    By:
    • Huang, Xiaojie;
    • Xu, Liumei;
    • Sun, Lijun;
    • Gao, Guiju;
    • Cai, Weiping;
    • Liu, Yanfen;
    • Ding, Haibo;
    • Wei, Hongxia;
    • Ma, Ping;
    • Wang, Min;
    • Liu, Shuiqing;
    • Chen, Yaokai;
    • Chen, Xiaohong;
    • Zhao, Qingxia;
    • Yu, Jianhua;
    • Song, Yuxia;
    • Chen, Hui;
    • Wu, Hao;
    • Qin, Shanfang;
    • Li, Linghua
    Publication type:
    Article
    7
    8
    9

    Pharmacokinetics and Safety of a Raltegravir-Containing Regimen in Children Aged 4 Weeks to 2 Years Living With Human Immunodeficiency Virus and Receiving Rifampin for Tuberculosis.

    Published in:
    Journal of the Pediatric Infectious Diseases Society, 2021, v. 10, n. 2, p. 201, doi. 10.1093/jpids/piaa039
    By:
    • Krogstad, Paul;
    • Samson, Pearl;
    • Acosta, Edward P;
    • Moye, Jack;
    • Townley, Ellen;
    • Bradford, Sarah;
    • Brown, Emily;
    • Denson, Kayla;
    • Graham, Bobbie;
    • Hovind, Laura;
    • Sise, Thucuma;
    • Teppler, Hedy;
    • Mathiba, Sisinyana Ruth;
    • Fairlie, Lee;
    • Winckler, Jana L;
    • Slade, Gretchen;
    • Meyers, Tammy;
    • Team, International Maternal Pediatric Adolescent AIDS Clinical Trials Network P1101
    Publication type:
    Article
    10

    Pharmacokinetics and 48-Week Safety and Efficacy of Raltegravir for Oral Suspension in Human Immunodeficiency Virus Type-1-Infected Children 4 Weeks to 2 Years of Age.

    Published in:
    Journal of the Pediatric Infectious Diseases Society, 2015, v. 4, n. 4, p. e76, doi. 10.1093/jpids/piu146
    By:
    • Nachman, Sharon;
    • Alvero, Carmelita;
    • Acosta, Edward P.;
    • Teppler, Hedy;
    • Homony, Brenda;
    • Graham, Bobbie;
    • Fenton, Terence;
    • Xia Xu;
    • Rizk, Matthew L.;
    • Spector, Stephen A.;
    • Frenkel, Lisa M.;
    • Worrell, Carol;
    • Handelsman, Edward;
    • Wiznia, Andrew
    Publication type:
    Article
    11
    12
    13
    14

    Incidence of cardiometabolic outcomes among people living with HIV‐1 initiated on integrase strand transfer inhibitor versus non‐integrase strand transfer inhibitor antiretroviral therapies: a retrospective analysis of insurance claims in the United States

    Published in:
    Journal of the International AIDS Society, 2023, v. 26, n. 6, p. 1, doi. 10.1002/jia2.26123
    By:
    • Rebeiro, Peter F.;
    • Emond, Bruno;
    • Rossi, Carmine;
    • Bookhart, Brahim K.;
    • Shah, Aditi;
    • Caron‐Lapointe, Gabrielle;
    • Lafeuille, Marie‐Hélène;
    • Donga, Prina
    Publication type:
    Article
    15
    16

    Third‐line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource‐limited settings: ACTG A5288 strategy trial.

    Published in:
    Journal of the International AIDS Society, 2022, v. 25, n. 6, p. 1, doi. 10.1002/jia2.25905
    By:
    • Avihingsanon, Anchalee;
    • Hughes, Michael D.;
    • Salata, Robert;
    • Godfrey, Catherine;
    • McCarthy, Caitlyn;
    • Mugyenyi, Peter;
    • Hogg, Evelyn;
    • Gross, Robert;
    • Cardoso, Sandra W.;
    • Bukuru, Aggrey;
    • Makanga, Mumbi;
    • Badal‐aesen, Sharlaa;
    • Mave, Vidya;
    • Ndege, Beatrice Wangari;
    • Fontain, Sandy Nerette;
    • Samaneka, Wadzanai;
    • Secours, Rode;
    • Van Schalkwyk, Marije;
    • Mngqibisa, Rosie;
    • Mohapi, Lerato
    Publication type:
    Article
    17
    18
    19
    20
    21
    22

    Raltegravir plus abacavir/lamivudine in virologically suppressed HIV-1-infected patients: 48-week results of the KIRAL study.

    Published in:
    PLoS ONE, 2018, v. 13, n. 6, p. 1, doi. 10.1371/journal.pone.0198768
    By:
    • Troya, Jesús;
    • Montejano, Rocio;
    • Ryan, Pablo;
    • Gómez, Cristina;
    • Matarranz, Mariano;
    • Cabello, Alfonso;
    • Vera, Francisco;
    • Sepúlveda, María Antonia;
    • Santos, Ignacio;
    • Samperiz, Gloria;
    • Bachiller, Pablo;
    • Boix, Vicente;
    • Barrufet, Pilar;
    • Cervero, Miguel;
    • Sanz, José;
    • Solís, Javier;
    • Yllescas, María;
    • Valencia, Eulalia;
    • null, null
    Publication type:
    Article
    23
    24
    25
    26
    27
    28
    29
    30
    31
    32
    33
    34

    Lack of a Clinically Significant Pharmacokinetic Interaction between Etravirine and Raltegravir Using an Original Approach Based on Drug Metabolism, Protein Binding, and Penetration in Seminal Fluid: A Pharmacokinetic Substudy of the ANRS‐163 ETRAL Study

    Published in:
    Pharmacotherapy, 2019, v. 39, n. 4, p. 514, doi. 10.1002/phar.2242
    By:
    • Lê, Minh Patrick;
    • Valantin, Marc‐Antoine;
    • Assoumou, Lambert;
    • Soulie, Cathia;
    • Le Mestre, Soizic;
    • Weiss, Laurence;
    • Yazdanpanah, Yazdan;
    • Molina, Jean‐Michel;
    • Bouchaud, Olivier;
    • Raffi, François;
    • Reynes, Jacques;
    • Calvez, Vincent;
    • Marcelin, Anne‐Geneviève;
    • Costagliola, Dominique;
    • Katlama, Christine;
    • Peytavin, Gilles;
    • Duvivier, Claudine;
    • Goujard, Cécile;
    • Jeantils, Vincent;
    • Salmon, Dominique
    Publication type:
    Article
    35
    36

    Long-term successful control of super-multidrug-resistant human immunodeficiency virus type 1 infection by a novel combination therapy of raltegravir, etravirine, and boosted-darunavir.

    Published in:
    Journal of Infection & Chemotherapy (Springer Science & Business Media B.V.), 2011, v. 17, n. 1, p. 105, doi. 10.1007/s10156-010-0082-4
    By:
    • Nakamura, Hitomi;
    • Miyazaki, Naoko;
    • Hosoya, Noriaki;
    • Koga, Michiko;
    • Odawara, Takashi;
    • Kikuchi, Tadashi;
    • Koibuchi, Tomohiko;
    • Kawana-Tachikawa, Ai;
    • Fujii, Takeshi;
    • Miura, Toshiyuki;
    • Iwamoto, Aikichi
    Publication type:
    Article
    37
    38
    39
    40
    41
    42
    43
    44
    45
    46
    47
    48

    Tolerability of integrase inhibitors in a real-life setting.

    Published in:
    2017
    By:
    • Peñafiel, Judit;
    • de Lazzari, Elisa;
    • Padilla, Mireia;
    • Rojas, Jhon;
    • Gonzalez-Cordon, Ana;
    • Blanco, Jose L.;
    • Blanch, Jordi;
    • Marcos, Maria A.;
    • Lonca, Montserrat;
    • Martinez-Rebollar, Maria;
    • Laguno, Montserrat;
    • Tricas, Amparo;
    • Rodriguez, Ana;
    • Mallolas, Josep;
    • Gatell, Jose M.;
    • Martinez, Esteban
    Publication type:
    journal article
    49
    50